Netvax

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

Clostridium-perfringens-type-A alpha toxoid

Disponibbli minn:

Intervet International BV

Kodiċi ATC:

QI01AB08

INN (Isem Internazzjonali):

adjuvanted vaccine against necrotic enteritis of chickens due to Clostridium perfringens

Grupp terapewtiku:

Chicken

Żona terapewtika:

Immunologicals for aves

Indikazzjonijiet terapewtiċi:

For the active immunisation of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.To reduce mortality and the incidence and severity of lesions caused by Clostridium-perfringens-type-A-induced necrotic enteritis. Efficacy was demonstrated by challenge of chicks approximately three weeks after hatching.The onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure.The duration of passive transfer of immunity: 51 weeks following completion of the vaccination procedure.

Sommarju tal-prodott:

Revision: 2

L-istatus ta 'awtorizzazzjoni:

Withdrawn

Data ta 'l-awtorizzazzjoni:

2009-04-16

Fuljett ta 'informazzjoni

                                Medicinal product no longer authorised
17
B. PACKAGE LEAFLET
Medicinal product no longer authorised
18
PACKAGE LEAFLET FOR
Netvax emulsion for injection for chickens
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder :
Intervet International B.V.
Wim de Körverstraat 35
5831AN Boxmeer
The Netherlands
Manufacturer for the batch release:
S-P Veterinary Ltd
Breakspear Road South
Harefield
Uxbridge
Middlesex, UB9 6LS
United Kingdom
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Netvax emulsion for injection for chickens
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
One dose (0.5ml) contains:
Active substance:
_Clostridium perfringens_ Type A alpha toxoid
Not less than 6.8 IU *
Adjuvant
Light Mineral Oil
0.31 ml
Excipients
Thiomersal
0.035-0.05 mg
* International units per ml of rabbit serum determined by haemolysis
inhibition assay
4.
INDICATION(S)
For the active immunization of chickens to provide passive
immunisation against necrotic enteritis to
their progeny, during the laying period.
To reduce mortality and the incidence and severity of lesions caused
by _Clostridium perfringens_ Type
A induced necrotic enteritis. Efficacy was demonstrated by challenge
of chicks approximately three
weeks after hatching.
Medicinal product no longer authorised
19
The onset of passive transfer of immunity: 6 weeks following
completion of the vaccination procedure
The duration of passive transfer of immunity: 51 weeks following
completion of the vaccination
procedure
5.
CONTRAINDICATIONS
None
6.
ADVERSE REACTIONS
No systemic reactions to vaccination were seen following intramuscular
vaccination. Vaccination may
result in moderate swelling of the breast tissue which will resolve
within 30 days. Following the
second vaccination swelling may persist for at least 35 days. Swelling
was very common.
After administration of a double dose, local reactions may increase
slightly.
If you notice any seri
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Netvax emulsion for injection for chickens
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose (0.5ml) contains:
Active substance:
_Clostridium perfringens_ Type A alpha toxoid
Not less than 6.8 IU *
Adjuvant
Light Mineral Oil
0.31 ml
Excipients
Thiomersal
0.035-0.05 mg
* International units per ml of rabbit serum determined by haemolysis
inhibition assay
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Emulsion for injection
Off white oily emulsion.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Chickens
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunization of chickens to provide passive
immunisation against necrotic enteritis to
their progeny, during the laying period.
To reduce mortality and the incidence and severity of lesions caused
by _Clostridium perfringens_ Type
A induced necrotic enteritis. Efficacy was demonstrated by challenge
of chicks approximately three
weeks after hatching.
The onset of passive transfer of immunity: 6 weeks following
completion of the vaccination procedure
The duration of passive transfer of immunity: 51 weeks following
completion of the vaccination
procedure
4.3
CONTRAINDICATIONS
None
Medicinal product no longer authorised
3
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
None
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO
ANIMALS
To the user:
This product contains mineral oil. Accidental injection/self injection
may result in severe pain and
swelling, particularly if injected into a joint or finger, and in rare
cases could result in the loss of the
affected finger if prompt medical attention is not given.
If you are accidentally injected with this product, seek prompt
medical advice even if only a very
small amount is injected and take the package leaflet with yo
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 11-06-2014
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 11-06-2014
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 11-06-2014
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 11-06-2014
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 11-06-2014
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 11-06-2014
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 11-06-2014
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 11-06-2014
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 11-06-2014
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 11-06-2014
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 11-06-2014

Ara l-istorja tad-dokumenti